Novo Nordisk A/S (NYSE:NVO) Shares Sold by Financial Advocates Investment Management

Financial Advocates Investment Management decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 23.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 13,584 shares of the company’s stock after selling 4,165 shares during the quarter. Financial Advocates Investment Management’s holdings in Novo Nordisk A/S were worth $1,168,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Daymark Wealth Partners LLC increased its position in Novo Nordisk A/S by 1.8% in the 3rd quarter. Daymark Wealth Partners LLC now owns 6,402 shares of the company’s stock valued at $762,000 after acquiring an additional 112 shares during the period. Marcum Wealth LLC grew its stake in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Marcum Wealth LLC now owns 3,897 shares of the company’s stock valued at $464,000 after purchasing an additional 104 shares during the last quarter. Wedmont Private Capital increased its holdings in shares of Novo Nordisk A/S by 7.8% in the third quarter. Wedmont Private Capital now owns 11,120 shares of the company’s stock valued at $1,310,000 after purchasing an additional 809 shares during the period. Sanibel Captiva Trust Company Inc. raised its stake in shares of Novo Nordisk A/S by 6.5% during the third quarter. Sanibel Captiva Trust Company Inc. now owns 8,993 shares of the company’s stock worth $1,071,000 after purchasing an additional 547 shares during the last quarter. Finally, Boston Common Asset Management LLC lifted its holdings in shares of Novo Nordisk A/S by 8.9% during the third quarter. Boston Common Asset Management LLC now owns 50,293 shares of the company’s stock worth $5,988,000 after purchasing an additional 4,119 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.9 %

Shares of Novo Nordisk A/S stock opened at $86.39 on Friday. The company has a 50-day moving average of $91.86 and a two-hundred day moving average of $111.83. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $387.66 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.16 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Analysts Set New Price Targets

A number of brokerages have commented on NVO. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.